华润双鹤：关于全资子公司北京双鹤润创科技有限公司DC6001片获得药物临床试验批准通知书的公告

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., has received the Drug Clinical Trial Approval Notice for DC6001 tablets from the National Medical Products Administration [2] Group 1 - The approval signifies a significant step in the development of DC6001 tablets, indicating progress in the company's research and development efforts [2] - The announcement reflects the company's commitment to advancing its pharmaceutical portfolio and enhancing its market position [2]